|Bid||87.71 x 800|
|Ask||88.49 x 3000|
|Day's Range||89.01 - 90.13|
|52 Week Range||78.74 - 96.06|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||1.01|
|Expense Ratio (net)||0.13%|
Becton Dickinson & Co. said it expects to swing to fiscal first-quarter net earnings per share of $2.05, from a loss of 76 cents in the same period a year ago. Excluding non-recurring items, adjusted EPS is expected to rise to $2.70 from $2.48, above the FactSet consensus of $2.59. Revenue is expected to rise 35% to $4.16 billion, topping the FactSet consensus of $4.11 billion. The medical technology company affirmed its 2019 revenue growth outlook of 8.5% to 9.5%, and its adjusted EPS guidance of $12.05 to $12.15. The stock, which was still inactive in premarket trade, has lost 5.6% over the past three months, while the SPDR Health Care Select Sector ETF has declined 5.5% and the S&P 500 has given up 6.9%.
Merck & Co. or AbbVie: Which Is Performing Better This Month? On January 10, AbbVie’s market cap was $132.91 billion. Based on its closing price on January 10, the company had reported returns of 2.21% in the last week, 0.67% in the last month, and -6.74% in the last quarter.
Teva or Mylan: Which Is the Better Generic Play in January? ## TEVA’s price movements Teva Pharmaceutical (TEVA) is a leading global pharmaceutical company with a market cap of $17.21 billion as of January 8. On the day, the company closed at $17.68 on the NYSE, up 0.06% from its previous closing price. On January 2, Teva Pharmaceutical issued a press release announcing the settlement of an ongoing patent infringement litigation with Amgen (AMGN) related to the latter’s secondary hyperparathyroidism drug, Sensipar. Based on its closing price on January 8, the company had reported returns of 14.66% in the last week, -12.73% in the last month, and -17.77% in the last quarter. Teva Pharmaceutical had also reported returns of -27.09% in the last half year, -8.01% in the last year, and 14.66% YTD (year-to-date). Based on its closing price on January 8, the broader healthcare sector represented by the Health Care Select Sector SPDR ETF (XLV) had reported returns of 0.52% in the last week, -6.42% in the last month, and -7.77% in the last quarter. XLV had also reported returns of 0.37% in the last half year, 2.01% in the last year, and 0.52% YTD. ## Analysts’ recommendations and target prices for Teva The 12-month consensus analyst recommendation for Teva Pharmaceutical as of January 9 is a “hold.” The 12-month consensus target price for the company is $22.71, 28.45% higher than its closing price on January 8. The highest target price estimate for the company is $30, and the lowest target price estimate is $15. Of the 23 analysts covering Teva Pharmaceutical on January 9, two analysts have rated the company as a “strong buy,” three have rated it as a “buy,” 15 have rated it as a “hold,” and three have rated it as a “sell.” In the next article, we’ll discuss analysts’ recommendations for Mylan in greater detail. Continue to Next Part Browse this series on Market Realist: * Part 2 - What Are Analysts Recommending for Mylan in January? * Part 3 - Teva or Mylan: Who Has the More Promising Revenue Trajectory? * Part 4 - Teva or Mylan: Whose Earnings Are Growing Faster?
Illumina Inc. provided Wednesday a fourth-quarter revenue estimate that was above expectations, and provided a mixed outlook for 2019. The stock was still inactive in premarket trade. The genetics analysis company's Chief Executive Francis deSouza said at the J.P. Morgan Healthcare Conference that fourth-quarter revenue rose 11% from a year ago to $865 million, which was above the FactSet consensus of $862 million, while full-year revenue rose 21% to $3.3 billion. For 2019, deSouza said revenue growth is expected to be 13% to 14%, while the current FactSet consensus of $3.81 billion is about 15% above 2018 revenue of $3.3 billion. The company expects 2019 adjusted earnings per share, which excludes non-recurring items, of $6.50 to $6.60, compared with the current FactSet consensus of $6.44. Illumina's stock has lost 9.3% over the past three months, while the SPDR Health Care Select Sector ETF has declined 7.9% and the S&P 500 has shed 10.6%.
Three Healthcare Stocks Rallying Over 10% Today ## Three healthcare stocks The broader market is trading in the green territory today but largely on a mixed note compared to the volatility in the previous couple of sessions. At 11:40 AM ET, the S&P 500 Index (SPY), NASDAQ Composite Index (QQQ), and Dow Jones Industrial Average were trading with 0.8%, 1.1%, and 0.6% gains. However, some healthcare stocks (XLV)(VHT)(IBB) were making huge moves today. Let’s take a look. ## Loxo Oncology Today before the market opened, the American pharmaceutical giant Eli Lilly and Company (LLY) announced the acquisition of Loxo Oncology (LOXO). According to the agreement between the two companies, Eli Lilly will acquire Loxo for $235.00 per share in cash, which translates into approximately $8.0 billion. After the news came out, Loxo stock surged nearly 66.0% to $232.12. ## Sage Therapeutics The biopharmaceutical firm Sage Therapeutics (SAGE) revealed positive results of the Phase 3 ROBIN Study today. The outcome of the study suggested a “significant improvement” in women with postpartum depression (or PPD) who were treated with its SAGE-217 drug for two weeks. This news boosted investors’ confidence, and SAGE stock surged 62.1% to a day high of $158.09. ## Exact Sciences The molecular diagnostics firm Exact Sciences (EXAS) said today that it expects its fourth quarter of 2018 revenue between $142.5 million and $143.5 million, which reflected about a 64% rise in its revenue from the fourth quarter of the previous year. In a press release, the company said that it “completed approximately 292,000 Cologuard tests during the fourth quarter of 2018,” up about 66% year-over-year. Plus, Exact Sciences noted, “Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018.” These positive developments drove EXAS stock to rally today to post a day high of $72.78, up 11.0% from its previous session’s closing price. Note that in 2018, LOXO, LLY, and EXAS rose 66.4%, 37.0%, and 20.1%, respectively, while SAGE fell 41.8%.
Shares of Hologic Inc. ran up 4.7% in premarket trade Monday, after the medical technology company provided a fiscal first-quarter revenue outlook that was above expectations. The company said it expects revenue for the quarter ended Dec. 29 of $831 million, up 55 from a year ago, and above the FactSet consensus of $812 million. Among its largest business segments, the company expects breast health revenue to rise to $325 million from $288 million, above the FactSet consensus of $305 million, and expects diagnostics revenue to grow to $297 million from $285 million, better than expectations of $290 million. The company is expected to report full results in early February. The stock has slipped 3.3% over the past three months, while the SPDR Health Care Select Sector ETF has lost 8.8% and the S&P 500 has declined 12.3%.
Shares of Loxo Onocology Inc. were indicated up about 33% in premarket trade Monday, after the biopharmaceutical company agreed to be acquired by Eli Lilly & Co. in a deal valued at $8.0 billion. Lilly's stock fell 2.7% in ahead of the open. Under terms of the deal, Lilly will pay $235 in cash for each Loxo share outstanding, which represents a 68% premium to Friday's closing price of $139.87, and 24% above Loxo's record close of $189.96 on July 6, 2018. The deal is the largest in a series of acquisitions by Lilly to broaden its cancer treatment efforts, Lilly said. The deal is expected to close by the end of the first quarter. The company said it will provide an update to 2019 financial guidance, when it reports fourth-quarter results on Feb. 13. Loxo shares have lost 12.4% over the past three months and Lilly shares have eased 0.3%, while the SPDR Health Care Select Sector ETF has shed 8.8% and the S&P 500 has declined 12.3%.
Compared to other sectors, healthcare was sturdy in 2018 and while the sector looks close to being fairly valued, the group could offer more upside this year. The Health Care Select Sector SPDR ETF (XLV) , the largest healthcare ETF by assets, gained 6.30% last year. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.
Healthcare, the second-largest sector weight in the S&P 500, was the best-performing sector in the U.S. last year. The Health Care Select Sector SPDR ETF (XLV) , the largest healthcare ETF by assets, gained 6.30% last year and some analysts believe more upside is in store for the healthcare sector in 2019. Consequently, investors may also turn to defensive sectors that are less economically sensitive, such as health care.
Will Restructuring Initiatives Put GE Back on Growth Trajectory? As part of its June 2018 major restructuring plan, General Electric (GE) intends to spin off the Healthcare segment and turn it into a standalone entity. The move is believed to be another step by newly appointed CEO Larry Culp to optimize the company’s business and strengthen its liquidity position.
The non-farm payrolls for the US (IVV) (QQQ) were 155,000 in November, which underwhelmed economists’ consensus of 198,000. October’s non-farm payrolls (or NFP) were also revised down to 237,000 from 250,000 previously, while September’s NFP were revised higher by 1,000 to 119,000. After last month’s weaker job additions, economists are expecting payrolls to come in at 180,000, which is lower than the average for the first 11 months of 2018 but still healthy.
House Democrats have set up rules for the new Congress that give the Speaker of the House the authority to intervene in a federal court case challenging the constitutionality of Obamacare. A coalition of Democratic state attorneys general, led by California's Xavier Becerra, intends to appeal. Democrats about to take over control of the House of Representatives have moved to defend Obamacare from a court challenge that threatens to kill the landmark health-care reform law.
While there have been losers in most corner of the space, several ETFs still managed to end the year in green and are likely to continue outperforming in 2019 too.
An Overview of Pfizer’s Oncology and Vaccine Business(Continued from Prior Part)Prevnar 13 revenue Pfizer’s (PFE) Prevnar (or Prevenar) 13 is used to prevent pneumococcal diseases. In the first nine months of this year, Prevnar 13 sales grew ~5% YoY (year-over-year) to $4.
Pfizer’s (PFE) oncology revenue rose ~16% YoY (year-over-year) to $5.3 billion in the first nine months of this year. Its net oncology revenue grew 8% YoY to $3.4 billion in US markets and 35% YoY to $1.9 billion in international markets.
Ron Weiner of RDM Financial Group talks to Yahoo Finance's Julie Hyman and Adam Shapiro about where he sees growth in stocks right now.
Tony Dwyer, Canaccord Genuity, says new highs are coming this year. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Steve Grasso and Guy Adami.